Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending January 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the valuation of share plan transactions:
- Ordinary Share Price: 1,427.50 pence per share.
- ADS Price: $43.19 per American Depositary Share.
- Transaction Type: Notional increases in share interests following the re-investment of dividends paid on January 8, 2015.
Material Changes
The filing details specific increases in notional shareholdings for various executives and connected persons. There are no reported material changes to the company's operations, financial position, or strategic direction in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports on compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) regarding director transactions.
Investor Verification Points
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand when notional dividends will be paid out.
- Confirm the total aggregate value of the notional increases for all listed Directors and PDMRs.
- Review the dividend payment date of January 8, 2015, to correlate with the re-investment pricing.